<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753493</url>
  </required_header>
  <id_info>
    <org_study_id>0804M29861</org_study_id>
    <nct_id>NCT00753493</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients</brief_title>
  <official_title>Phase I Pharmacokinetic and Safety Study of Intravenous Topiramate in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to determine, in adult patients on maintenance topiramate therapy,
      the steady-state pharmacokinetics and safety of orally and intravenously administered
      topiramate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The long-term goal of this research project is to develop a more effective, safer therapy for
      neonatal seizures. Prior to using an investigational intravenous topiramate formulation in
      children and neonates, the pharmacokinetics and safety of the formulation must be
      demonstrated in adults. The immediate aims of this study are to determine the
      pharmacokinetics and safety of a novel intravenous topiramate formulation. An additional aim
      is to determine if sex, advancing age, or genotype affects topiramate absorption,
      distribution, or elimination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>96 hours after dosing</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Epilepsy</condition>
  <condition>Migraines</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a one arm pharmacokinetic and safety study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous topiramate</intervention_name>
    <description>Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Topamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons taking topiramate

          -  Persons 18 years of age and older

        Exclusion Criteria:

          -  Patients who are pregnant

          -  Patients who are breast feeding

          -  Patients with significant medical problems who may not tolerate intravenous
             administration

          -  Patients taking medications known to affect topiramate disposition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C Cloyd, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>July 12, 2012</last_update_submitted>
  <last_update_submitted_qc>July 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 2, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

